Nuritas will place new funding toward continued development of bioactive peptides through artificial intelligence and genomics
Nuritas, a biotechnology company that is revolutionizing the discovery and use of bioactive peptides through artificial intelligence (AI) and genomics, announced the close of a $20 million Series A funding round led by Chicago-based Cultivian Sandbox Ventures.
This brings the total invested to date to approximately $30 million, including early funding from U2's Bono and The Edge, Salesforce CEO Marc Benioff, Singapore-based VisVires New Protein and angel investor Ali Partovi. The latest round of funding will support Nuritas' growth in the United States (US) to address and solve many of the most pressing societal issues of the day, including the diabetes epidemic.
"Nuritas' unique platform delivers truly life-changing health benefits and we are very pleased to be involved in its growth – it's a brilliant team and such an exciting technology," said Nick Rosa, Managing Director of Cultivian Sandbox and Co-founder of Sandbox Industries. "We expect Nuritas to quickly emerge as one of the most innovative companies in the world, effecting real change."